Latest Licensing News

Titanium Sands Limited has secured one-year retentions for four high-grade exploration licenses, enabling critical environmental studies and paving the way for a mining license application in Sri Lanka.

Greenwing Resources confirms NIO Inc.'s subsidiary did not exercise its call option on Andes Litio SA, while advancing exploration at the San Jorge Lithium Project in Argentina.

Viridis Mining and Minerals, through its joint venture Viridion, has delivered the first batch of high-purity rare earth oxides recycled from Brazilian magnets to Latin America’s only magnet manufacturer, marking a key step in establishing a domestic rare earth supply chain.

InFocus Group Holdings has secured a $3.25 million contract to develop a cutting-edge white-label iGaming platform for Taiwanese firm TG Solutions, marking a significant expansion into the digital gaming sector.

Canyon Resources has locked in a US$140 million syndicated credit facility alongside a AU$24.5 million option exercise by a major shareholder, positioning the company to fast-track operations at its Minim Martap Bauxite Project in Cameroon.

Neuren Pharmaceuticals has approved a significant long-term equity incentive plan tied to critical clinical and regulatory milestones for its drug candidate NNZ-2591, reinforcing management’s commitment to shareholder value.

Constellation Resources Limited is raising approximately $2.52 million through a non-renounceable entitlement offer priced at $0.12 per share, aiming to fund exploration projects in Western Australia and support general working capital.

MTM Critical Metals has confirmed the scalability of its Flash Joule Heating reactor, paving the way for commercial operations at its Texas facility later this year. The modular design promises potential throughput beyond initial targets.

Provaris Energy has partnered with Yinson to develop large-scale liquid CO2 storage tanks and shipping solutions, aiming to meet surging demand in the expanding carbon capture and storage market.

Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.